3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 1
1
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
2
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
24
Neoplasm Metastasis
8
Leukemia, Myeloid, Acute
8
Carcinoma, Renal Cell
7
Ovarian Neoplasms
6
Lymphoma, Non-Hodgkin
6
Carcinoma, Non-Small-Cell Lung
6
Stomach Neoplasms
5
Colorectal Neoplasms
5
Breast Neoplasms
5
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
4
Neuroblastoma
4
Neoplasms
4
Lymphoma
4
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Esophageal Neoplasms
3
Colonic Neoplasms
3
Uveal Melanoma
2
Urinary Bladder Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Rectal Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Multiple Myeloma
2
Mesothelioma, Malignant
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Interventions
Temozolomide
69
Radiotherapy
30
Bevacizumab
24
Carboplatin
13
pembrolizumab
12
Radiation
11
Carmustine
8
Irinotecan
7
temsirolimus
6
Surgical Procedures, Operative
6
Radiosurgery
6
Erlotinib Hydrochloride
6
atezolizumab
5
Vorinostat
5
Sirolimus
5
Radiotherapy, Intensity-Modulated
5
Nivolumab
5
Lomustine
5
Everolimus
5
fludarabine
4
Radiotherapy, Conformal
4
Magnetic Resonance Spectroscopy
4
Cyclophosphamide
4
Aminolevulinic Acid
4
tipifarnib
3
Sorafenib
3
Paclitaxel
3
IL13-PE38
3
Granulocyte-Macrophage Colony-Stimulating Factor
3
Gemcitabine
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Glioblastoma
×
Interleukin-2
×
Clear all
NCT07410494
2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2
Recruiting
85 enrolled
NCT06640582
2024-11-05
BAH2472
Essen Biotech
Phase 1/2
Recruiting
85 enrolled